Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1760844 | 0.91 | GBA1 (0.47) | GBA1HTR3AALDH1A1 | |
| SCHEMBL13576643 | 0.89 | KCNH2 (0.53) | HTR3AALDH1A1HRH4HRH3KCNH2 | |
| SCHEMBL13576618 | 0.89 | KCNH2 (0.53) | HTR3AALDH1A1HRH4HRH3KCNH2 | |
| SCHEMBL894700 | 0.89 | GBA1 (0.66) | GBA1HTR3AALDH1A1HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL6968488 | 0.87 | GBA1 (0.63) | GBA1HTR3AALDH1A1KCNH2SLC6A2 | |
| SCHEMBL3914733 | 0.84 | SLC6A4 (0.50) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29090963 | 0.82 | SLC6A4 (0.49) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1814200 | 0.81 | GBA1 (0.52) | GBA1HRH4HRH3KCNH2SLC6A2 | |
| SCHEMBL1994022 | 0.81 | GBA1 (0.52) | GBA1HRH4HRH3SLC6A2SLC6A4 | |
| SCHEMBL1811296 | 0.81 | GBA1 (0.52) | GBA1HRH4HRH3KCNH2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102695546-B | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2014-09-10 | — | — | CN | disclosed |
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| CN-101228138-B | Neurotherapeutic azole compounds | SK HOLDINGS CO LTD | 2012-11-21 | — | — | CN | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| CN-101228138-A | Neurotherapeutic azole compounds | SK HOLDINGS CO LTD (KR) | 2008-07-23 | — | — | CN | disclosed |
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
| CN-1229343-C | Novel compounds | ASTRAZENECA AB (SE) | 2005-11-30 | — | — | CN | disclosed |
| US-6951874-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| CN-1426412-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| CN-1426393-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| CN-1426394-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-25 | — | — | CN | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | GBA1 993/4885HTR3A 446/4885ALDH1A1 1039/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | GBA1 926/4885HTR3A 2557/4885ALDH1A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.